Isolator Technology for Aseptic Filling of High Potent Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Isolator Technology for Aseptic Filling of High Potent Products


PIERRE FABRE MEDICAMENT PRODUCTION owns a manufacturing site in the south of France, which has some of the largest experience worldwide with 22 years usage of isolator technology for aseptic filling of high potent freeze-dried injectable products.

Its newest generation of cytotoxic suites were built a few years ago to manufacture new products in compliance with worldwide CGMP and European ATEX regulation. All process operations: dispensing, compounding, filling, lyophilization, capping and external decontamination of the vial, are done under isolator technology. PFMP has developed an innovative filling line with Washing In Place system and Sterilization In Place system of the isolators with built-in Vaporized Hydrogen Peroxyde generator. These two new suites were granted “Most Advanced Facility of the Year” by European Outsourcing Awards in 2008.

PFMP proposes to its partners a full CDMO service with full Development of Product and Active Ingredient, Contract Manufacturing of API and Finish Product including freeze-drying cycle development. Its main objective is always to offer process technology innovation to manufacture future products and to guaranty the compliance with the evolution of the Quality criteria as well as the Environmental and Safety conditions.

PIERRE FABRE MEDICAMENT PRODUCTION
Contact: Franck PAVAN, Outsourcing & Business Development Manager
Email: franck.pavan@pierre-fabre.com
Website: www.aquitaine-pharm.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here